Board Meeting Details

The Board of Directors meeting was held on October 29, 2026, commencing at 03:00 PM (IST) and concluding at 06:50 PM (IST).

Key Approvals

A. Unaudited Financial Results

  • Approved unaudited financial results (standalone and consolidated) for quarter and half year ended September 30, 2026
  • Results reviewed by statutory auditors SRBC & CO LLP
  • Limited Review Reports issued by auditors

B. Revised Policy on Related Party Transactions

  • Amended Policy on Related Party Transactions approved
  • Policy will be available on company website: www.rpglifesciences.com

Trading Window Closure

  • Trading window for dealing in company securities shall open post 48 hours after declaration of financial results

Standalone Financial Results (₹ in Lakhs)

Quarterly Performance (Q2 FY27 vs Q2 FY26 vs Q1 FY27)

  • Revenue from Operations: ₹19,339 (Q2 FY27) vs ₹18,168 (Q2 FY26) vs ₹19,569 (Q1 FY27)
  • Other Income: ₹377 (Q2 FY27) vs ₹454 (Q2 FY26) vs ₹416 (Q1 FY27)
  • Total Income: ₹19,716 (Q2 FY27) vs ₹18,622 (Q2 FY26) vs ₹19,985 (Q1 FY27)
  • Profit Before Tax: ₹3,008 (Q2 FY27) vs ₹4,945 (Q2 FY26) vs ₹4,121 (Q1 FY27)
  • Profit After Tax: ₹2,329 (Q2 FY27) vs ₹3,685 (Q2 FY26) vs ₹3,057 (Q1 FY27)
  • Basic EPS: ₹14.08 (Q2 FY27) vs ₹22.28 (Q2 FY26) vs ₹18.49 (Q1 FY27)

Half-Yearly Performance (H1 FY27 vs H1 FY26)

  • Revenue from Operations: ₹38,908 (H1 FY27) vs ₹35,060 (H1 FY26)
  • Total Income: ₹39,701 (H1 FY27) vs ₹36,037 (H1 FY26)
  • Profit Before Tax: ₹7,129 (H1 FY27) vs ₹8,488 (H1 FY26)
  • Profit After Tax: ₹5,386 (H1 FY27) vs ₹6,314 (H1 FY26)
  • Basic EPS: ₹32.57 (H1 FY27) vs ₹38.18 (H1 FY26)

Exceptional Items

  • Q2 FY25: Gain of ₹1,122 lakhs on account of fire incident
  • FY26: Net exceptional income of ₹390 lakhs comprising:
  • Insurance claim settlement: ₹2,475 lakhs (net income)
  • New Labour Codes impact: ₹(1,169) lakhs expense
  • Intangible asset impairment: ₹(916) lakhs

Consolidated Financial Results (₹ in Lakhs)

Quarterly Performance (Q2 FY27 vs Q2 FY26 vs Q1 FY27)

  • Revenue from Operations: ₹21,164 (Q2 FY27) vs ₹18,168 (Q2 FY26) vs ₹19,569 (Q1 FY27)
  • Other Income: ₹426 (Q2 FY27) vs ₹454 (Q2 FY26) vs ₹416 (Q1 FY27)
  • Total Income: ₹21,590 (Q2 FY27) vs ₹18,622 (Q2 FY26) vs ₹19,985 (Q1 FY27)
  • Profit Before Tax: ₹3,704 (Q2 FY27) vs ₹4,945 (Q2 FY26) vs ₹4,122 (Q1 FY27)
  • Profit After Tax: ₹2,822 (Q2 FY27) vs ₹3,685 (Q2 FY26) vs ₹3,058 (Q1 FY27)
  • Attributable to owners: ₹2,660 (Q2 FY27)
  • Non-controlling interest: ₹162 (Q2 FY27)
  • Basic EPS: ₹17.07 (Q2 FY27) vs ₹22.28 (Q2 FY26) vs ₹18.49 (Q1 FY27)

Half-Yearly Performance (H1 FY27 vs H1 FY26)

  • Revenue from Operations: ₹40,733 (H1 FY27) vs ₹35,060 (H1 FY26)
  • Total Income: ₹41,575 (H1 FY27) vs ₹36,037 (H1 FY26)
  • Profit Before Tax: ₹7,825 (H1 FY27) vs ₹8,488 (H1 FY26)
  • Profit After Tax: ₹5,879 (H1 FY27) vs ₹6,314 (H1 FY26)
  • Attributable to owners: ₹5,717 (H1 FY27)
  • Non-controlling interest: ₹162 (H1 FY27)
  • Basic EPS: ₹35.55 (H1 FY27) vs ₹38.18 (H1 FY26)

Significant Corporate Developments

1. API Business Transfer

  • Business Transfer Agreement dated July 29, 2026 for transfer of API Business to RPG Active Pharma Limited (wholly owned subsidiary)
  • Transfer on slump sale basis as going concern for consideration of ₹3,355 lakhs
  • Transaction consummated on August 15, 2026
  • Financial results reflect impact of this transaction and are not strictly comparable with previous periods

2. Investment in RPGAP

  • Investment and Shareholders' Agreement among Company, RPGAP, India Life Sciences Fund IV Domestic (ILSF) and Vistaject Fund (VJF)
  • ILSF and VJF invested aggregate ₹24,330 lakhs in RPGAP by subscribing to equity shares and Compulsorily Convertible Preference Shares (CCPS)
  • CCPS allotted on September 9, 2026
  • CCPS classified as financial liability in financial results
  • Company continues to exercise control over RPGAP, which remains consolidated subsidiary

3. Acquisitions by RPGAP

a) Business Acquisition from Raghava Life Sciences Private Limited

  • Acquired API and intermediates businesses as going concern on slump sale basis
  • Consideration: Up to ₹14,381 lakhs
  • Effective date: September 16, 2026
  • Portion of purchase consideration subject to hold back

b) Equity Acquisition of Actis Generics Private Limited

  • Acquired entire equity share capital pursuant to Share Purchase Agreement
  • Consideration: Up to ₹8,783 lakhs
  • Effective date: September 24, 2026
  • Actis became wholly owned subsidiary of RPGAP and subsidiary of Company
  • Portion of purchase consideration subject to hold back

4. Scheme of Amalgamation

  • Board of RPGAP approved Scheme of Amalgamation of Actis with RPGAP under Companies Act, 2013
  • Scheme subject to NCLT, shareholder, and other regulatory approvals

Financial Position

Standalone Balance Sheet (as of September 30, 2026)

  • Total Assets: ₹77,538 lakhs (vs ₹79,314 lakhs as of March 31, 2026)
  • Total Equity: ₹61,924 lakhs (vs ₹60,537 lakhs as of March 31, 2026)
  • Investments: ₹16,700 lakhs (current and non-current)
  • Cash and cash equivalents: ₹10,180 lakhs

Consolidated Balance Sheet (as of September 30, 2026)

  • Total Assets: ₹111,640 lakhs (vs ₹79,314 lakhs as of March 31, 2026)
  • Total Equity: ₹86,646 lakhs (vs ₹60,537 lakhs as of March 31, 2026)
  • Equity attributable to parent: ₹68,721 lakhs
  • Non-controlling interest: ₹17,925 lakhs
  • Goodwill: ₹675 lakhs
  • Other intangible assets: ₹4,868 lakhs

Cash Flow Statements

Standalone Cash Flows (H1 FY27)

  • Net cash from operating activities: ₹2,308 lakhs
  • Net cash from investing activities: ₹258 lakhs
  • Net cash from financing activities: ₹(3,956) lakhs (including dividend payment of ₹3,969 lakhs)
  • Net decrease in cash: ₹(1,388) lakhs

Consolidated Cash Flows (H1 FY27)

  • Net cash from operating activities: ₹1,049 lakhs
  • Net cash from investing activities: ₹(25,742) lakhs (including acquisitions and investments)
  • Net cash from financing activities: ₹20,699 lakhs (including equity issue proceeds of ₹24,273 lakhs)
  • Net decrease in cash: ₹(3,995) lakhs

Notes to Financial Results

1. Segment Information

  • Company operates in only one reportable business segment: Pharmaceuticals

2. Insurance Claim Settlement

  • Full settlement received for fire incident at Navi Mumbai API plant (January 2025)
  • ₹2,475 lakhs recognized as exceptional income in FY26
  • ₹791 lakhs received for business interruption losses recognized as other income in Q4 FY26

3. New Labour Codes Impact

  • Exceptional expense of ₹1,169 lakhs recognized in FY26 due to New Labour Codes effective November 22, 2025
  • Impact primarily from change in wage definition

4. Intangible Asset Impairment

  • Write-off of intangible asset under development of ₹916 lakhs in FY26
  • Based on management assessment showing no future economic benefits

5. Acquisition Accounting

  • Acquisitions accounted under Ind AS 103 (Business Combinations)
  • Purchase price allocations provisional pending completion of valuation
  • Final allocations may differ from current financial results